Sam Horng is a Neurology physician affiliated with Mount Sinai Health System. OpenAlex indexes 34 publications with 1,104 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5 E 98th St
Suite 1138
New York, NY 100296501
Telephone
212-241-6854Registry record last updated 6 Aug 2019.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
52.3%Gabapentinoids15.6%Gabapentin100%Part D<11 patientsPotassium Channel Blocker12.8%Dalfampridine Er100%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
31.7%Other immunostimulants15.6%Glatiramer Acetate59%Copaxone41%Part D<11 patientsCD20-directed Cytolytic Antibody11%Kesimpta Pen100%Part D<11 patients+ 1 more class in this area
Cardiovascular
8.3%Statin8.3%Simvastatin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2018–2022 per NIH RePORTER. The latest:
- Astrocytic control of lymphocyte migration and differentiation in CNS inflammatory lesions
Icahn School of Medicine at Mount Sinai
FY2022$193,320K08NS102507 - Astrocytic control of lymphocyte migration and differentiation in CNS inflammatory lesions
Icahn School of Medicine at Mount Sinai
FY2021$193,320K08NS102507 - Astrocytic control of lymphocyte migration and differentiation in CNS inflammatory lesions
Icahn School of Medicine at Mount Sinai
FY2020$193,320K08NS102507
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Stamatios Lerakis, MD
Mount Sinai Health System
Stanley Yancovitz, MD
Mount Sinai Health System
Vivek Yerrapu Reddy
Mount Sinai Health System
Robert Desnick, PhD, MD
Mount Sinai Health System
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”